Phase III SQUIRE Trial in Patients With NSCLC Treated With Necitumumab

July 28, 2015
Martin Reck, MD, PhD

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial in patients with non-small cell lung cancer (NSCLC) treated with necitumumab.

Reck says the rash was the only major adverse event observed, but it is easily manageable. Doses can be modified and topical treatments can be used.

Reck and his team are pleased with the results and improvements of the trial, and they believe it has presented a crucial new option for the treatment paradigm.

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial, which investigated patients with non-small cell lung cancer (NSCLC) treated with necitumumab.